2015 Conference on Retroviruses and Opportunistic Infections

2015 Conference on Retroviruses and Opportunistic Infections | CROI 2015

CROI 2015 "brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases."

Conference Coverages

Kidney Disease Risk Higher with Longer Exposure to Antiretrovirals, Study Finds
Kidney Disease Risk Higher with Longer Exposure to Antiretrovirals, Study Finds
Chronic kidney disease developed in association with exposure to antiretrovirals in people with initially normal levels of estimated glomerular filtration rate (eGFR) was not limited to increased incidence immediately after starting therapy but in fact increased over time and exposure.
New Formulation Compares Favorably to Current, Commonly Used Tenofovir Dose
Tenofovir alafenamide, which results in 90% lower circulating plasma tenofovir than standard tenofovir disoproxil fumarate, is associated with similar virologic response rates as the standard regimen, but with an improved safety profile.
NS5A/ NS3 Combo Hepatitis C Treatment Delivers Excellent Sustained Virologic Response in Patients Coinfected with HIV
Combination treatment with daclatasvir and asunaprevir plus interferon/ribavirin had high success rates in a 24-week clinical trial for treatment of hepatitis C in patients coninfected with HIV.
Combo Drug Shows High Hepatitis C Cure Rates in Patients Coinfected with HIV
An interferon/ribavirin-free pill that combines two drugs to treat patients with certain genotypes of hepatitis C who are also infected with HIV was found to be highly effective in a 12-week trial, clearing the hepatitis C virus from almost all the patients involved.
New Class of HIV Drug Shows Promise in Initial Study
Novel second-generation HIV-1 maturation inhibitor shows favorable antiviral activity and safety profile in HIV-1, subtype B-infected subjects
Statin Therapy for Atherosclerosis in HIV-Infected Patients
Study results show that treatment with atorvastatin lowers LDL-cholesterol levels and reduces the volume of noncalcified and high-risk plaques in HIV-infected patients with subclinical atherosclerosis.
More News on the FACTS 001 Trial and Approaches to HIV Prevention in Women
Cultural barriers, poor treatment adherence, and other factors thwart efforts to provide effective anti-HIV acquisition measures for women in Africa.
Higher Dose of Drug May Reduce Treatment Time for Patients with Tuberculosis
A high dose of rifampin and moxifloxacin in combination with standard drug treatment could cut the length of time needed to successfully treat patients for tuberculosis.
PrEP for HIV Prevention: Where We Are and Where Do We Need to Go?
Pre-exposure prophylaxis (PrEP) is a strategy with significant historical precedent in the infectious disease field. Applied to HIV prevention, at-risk individuals would take PrEP to protect against HIV acquisition in case of any planned or unplanned exposure, potentially permitting HIV prophylactic control by the uninfected individual.

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$